Stocks · News reference
Hemab Therapeutics Hldgs (NASDAQ:COAG) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.52) by 53.85 percent. This is a 93.8 percent increase over losses of $(12.91) per
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Wedbush analyst David Nierengarten maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and raises the price target from $55 to $64.
Read original at benzingaHC Wainwright & Co. analyst Emily Bodnar maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and raises the price target from $52 to $60.
Read original at benzingaFiled: 2026-08-11 AccNo: 0001193125-26-343421 Size: 251 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar